{"id":6854,"date":"2022-07-22T13:19:45","date_gmt":"2022-07-22T11:19:45","guid":{"rendered":"https:\/\/copolad.eu\/?p=6854"},"modified":"2022-07-22T13:23:22","modified_gmt":"2022-07-22T11:23:22","slug":"emcdda-becomes-official-partner-of-copolad-iii","status":"publish","type":"post","link":"https:\/\/copolad.fiiapp.quentalstaging.com\/en\/emcdda-becomes-official-partner-of-copolad-iii\/","title":{"rendered":"EMCDDA becomes official partner of COPOLAD III"},"content":{"rendered":"<p class=\"Default\">The\u00a0 <a href=\"https:\/\/www.emcdda.europa.eu\/emcdda-home-page_en\">European Monitoring Center for Drugs and Drug Abbuse (EMCDDA<\/a>) becomes an official partner of <a href=\"https:\/\/copolad.eu\/en\/\">COPOLAD III, <\/a>\u00a0a programme promoting dialogue and bi-regional cooperation on drug policy between the European Union and Latin American and Caribbean countries (LAC). Funded by the EU, the programme is led by the International Ibero-American Foundation for Public Policies and Administrations (FIIAPP), in consortium with the Italian-Latin American International Organization (IILA). Collaborating in the programme are the <b>Deutsche Gesellschaft f\u00fcr Internationale Zusammenarbeit GmbH (GIZ) (<sup>2<\/sup>) and the EMCDDA.<\/b><\/p>\n<p class=\"Default\">The programme, which began in February 2021, will run until January 2025 with a total budget of EUR 15 million. The EMCDDA signed a grant agreement with IILA today for EUR 800 000. This paves the way for a range of activities supporting LAC countries through a stronger focus on data collection, evidence-based policies and research.<\/p>\n<p class=\"Default\">The agreement (which will run until October 2024), will see the EMCDDA support FIIAPP and the IILA in delivering the following programme outputs:<\/p>\n<ul>\n<li class=\"Default\"><b>strengthened technical capacity and institutional role of the national drug observatories (NDOs);<\/b><\/li>\n<li class=\"Default\"><b>improved coherence, balance, quality and evidence base of drug demand reduction policies in LAC countries;<\/b><\/li>\n<li class=\"Default\"><b>effective strengthening of cooperation in drug trafficking investigative activities;<\/b><\/li>\n<li class=\"Default\"><b>enhanced support for the political\u2013technical dialogue between EU and LAC regions on drug-related issues.<\/b><\/li>\n<\/ul>\n<p class=\"Default\">When delivering the activities, the agency will apply co-production and co-ownership principles and adopt a multiple stakeholder and multi-disciplinary approach. It will also use <b>EMCDDA toolboxes and resources for data collection and analysis. These cover: key epidemiological and market indicators; early-warning system methods;<\/b> prevention platforms and tools; and health and social responses guides. Methods will be adapted to national circumstances and tools will be translated where necessary.<\/p>\n<p class=\"Default\">Activities will address the need to i<b>ncrease national capacity to better use information for policies and action.<\/b> This will be done through targeted training activities and co-production workshops to develop tailored outputs to support practice configured to local needs.<\/p>\n<p class=\"Default\">Initially launched in 2011, COPOLAD aims to identify common priorities and coordinate policies to tackle challenges related to the global drugs problem. The EMCDDA provided ad-hoc support to the first two phases of the project: COPOLAD I (2011\u201315) and COPOLAD II (2016\u2013 2020).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The\u00a0 European Monitoring Center for Drugs and Drug Abbuse (EMCDDA) becomes an official partner of COPOLAD III, \u00a0a programme promoting dialogue and bi-regional cooperation on drug policy between the European Union and Latin American and Caribbean countries (LAC). Funded by the EU, the programme is led by the International Ibero-American Foundation for Public Policies and [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":6851,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[102,112],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/en\/wp-json\/wp\/v2\/posts\/6854"}],"collection":[{"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/en\/wp-json\/wp\/v2\/comments?post=6854"}],"version-history":[{"count":0,"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/en\/wp-json\/wp\/v2\/posts\/6854\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/en\/wp-json\/wp\/v2\/media\/6851"}],"wp:attachment":[{"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/en\/wp-json\/wp\/v2\/media?parent=6854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/en\/wp-json\/wp\/v2\/categories?post=6854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/en\/wp-json\/wp\/v2\/tags?post=6854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}